Arizona State Retirement System raised its holdings in Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) by 224.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 128,388 shares of the biotechnology company’s stock after purchasing an additional 88,854 shares during the period. Arizona State Retirement System owned 0.17% of Momenta Pharmaceuticals worth $1,791,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Principal Financial Group Inc. increased its stake in shares of Momenta Pharmaceuticals by 12.0% in the third quarter. Principal Financial Group Inc. now owns 606,700 shares of the biotechnology company’s stock worth $11,224,000 after purchasing an additional 65,014 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Momenta Pharmaceuticals in the third quarter worth about $1,141,000. Sectoral Asset Management Inc boosted its position in shares of Momenta Pharmaceuticals by 24.4% in the third quarter. Sectoral Asset Management Inc now owns 372,499 shares of the biotechnology company’s stock valued at $6,891,000 after acquiring an additional 73,099 shares during the period. Legal & General Group Plc boosted its position in shares of Momenta Pharmaceuticals by 21.4% in the third quarter. Legal & General Group Plc now owns 154,060 shares of the biotechnology company’s stock valued at $2,851,000 after acquiring an additional 27,173 shares during the period. Finally, Fisher Asset Management LLC boosted its position in shares of Momenta Pharmaceuticals by 26.4% in the fourth quarter. Fisher Asset Management LLC now owns 124,507 shares of the biotechnology company’s stock valued at $1,737,000 after acquiring an additional 25,984 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.
In other Momenta Pharmaceuticals news, Director Elizabeth Stoner sold 5,500 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $13.10, for a total transaction of $72,050.00. Following the completion of the sale, the director now directly owns 13,240 shares in the company, valued at $173,444. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Craig A. Wheeler sold 35,666 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $14.11, for a total transaction of $503,247.26. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 112,002 shares of company stock valued at $1,733,746. 4.40% of the stock is currently owned by company insiders.
Momenta Pharmaceuticals, Inc. (MNTA) opened at $18.70 on Tuesday. Momenta Pharmaceuticals, Inc. has a 1 year low of $11.85 and a 1 year high of $19.25. The company has a market cap of $1,440.00, a P/E ratio of -15.33 and a beta of 1.71.
Momenta Pharmaceuticals (NASDAQ:MNTA) last announced its earnings results on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.12. Momenta Pharmaceuticals had a negative net margin of 63.43% and a negative return on equity of 23.62%. The business had revenue of $64.60 million during the quarter, compared to analyst estimates of $66.59 million. During the same period in the previous year, the business posted $0.60 earnings per share. Momenta Pharmaceuticals’s revenue for the quarter was up 88.9% on a year-over-year basis. equities analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 EPS for the current fiscal year.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Want to see what other hedge funds are holding MNTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA).
Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.